Serological survey to determine measles and rubella immunity gaps across age and geographic locations in The Gambia: a study protocol
- PMID: 40833299
- PMCID: PMC12372506
- DOI: 10.1080/16549716.2025.2540135
Serological survey to determine measles and rubella immunity gaps across age and geographic locations in The Gambia: a study protocol
Abstract
Vaccine coverage and disease surveillance data are valuable for monitoring protection against vaccine-preventable diseases; however, they do not directly measure population immunity. High-quality, representative serological studies can provide key insights into immunity gaps, outbreak susceptibility, and inform targeted vaccination strategies, even in high-performing immunization programs. This study aims to estimate location-specific and age-specific immunity profiles for measles and rubella while evaluating the predictive value of indirect immunity estimates derived from vaccination and surveillance data against direct serological measurements. Additionally, it seeks to model the risk of measles outbreaks and assess the impact of mitigation strategies. A multi-stage, stratified cluster sampling design will be implemented across six districts in The Gambia's North Bank and Upper River Regions. Survey clusters (i.e. 5 km × 5 km areas) encompassing all settlements within their boundaries will be selected, proportionally to district population sizes. Cluster selection ensures representativeness of both the population and vaccine coverage within each district. Based on detecting a 10% difference in protective immunity across vaccine coverage levels, power analysis assumes an intraclass correlation coefficient (ICC) of 0.01. In each cluster, 70 children aged 9 months to 14 years will be recruited, yielding a total sample size of 1,750 children across 25 selected clusters. Dried blood samples will be collected and tested for anti-measles and anti-rubella IgG using enzyme immunoassays (EIA). District-specific measles seroprevalence will be estimated using a hierarchical spatial model. This study will generate key evidence needed to refine immunization strategies and reduce the risk of measles and rubella outbreaks.
Keywords: Measles; immunity; rubella; serology; serosurvey.
Plain language summary
Added knowledge Representative measles and rubella serological studies can provide critical insights into immunity gaps, outbreak susceptibility, and targeted vaccination strategies, even in high-performing immunization programs.Global health impact on policy and action This study will generate serological data to identify immunity gaps, refine immunization strategies, and strengthen measles and rubella outbreak prevention strategies in The Gambia.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures



Similar articles
-
Seroprevalence of Immunoglobulin G against measles and rubella over a 12-year period (2009-2021) in Kilifi, Kenya and the impact of the Measles-Rubella (MR) vaccine campaign of 2016.Vaccine. 2025 Aug 13;61:127425. doi: 10.1016/j.vaccine.2025.127425. Epub 2025 Jun 21. Vaccine. 2025. PMID: 40544796
-
Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination in the US.JAMA. 2025 Jun 24;333(24):2176-2187. doi: 10.1001/jama.2025.6495. JAMA. 2025. PMID: 40272967
-
Immunogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial.Lancet Child Adolesc Health. 2025 May;9(5):306-314. doi: 10.1016/S2352-4642(25)00090-2. Epub 2025 Mar 31. Lancet Child Adolesc Health. 2025. PMID: 40179934 Free PMC article. Clinical Trial.
-
Vaccines for measles, mumps and rubella in children.Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD004407. doi: 10.1002/14651858.CD004407.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2020 Apr 20;4:CD004407. doi: 10.1002/14651858.CD004407.pub4. PMID: 22336803 Free PMC article. Updated.
-
The end of measles and congenital rubella: an achievable dream?Ann Ig. 2017 Jan-Feb;29(1):1-26. doi: 10.7416/ai.2017.2128. Ann Ig. 2017. PMID: 28067934
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical